ELI LILLY & CO (LLY)
US5324571083 - Common Stock
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
The second wave of the weight loss drug stock boom is underway and investors should heed the signs the market is serving.
This 1 Simple ETF Could Turn $100 a Month Into $93,200
Turn small investments into big returns with this surprisingly simple strategy -- and a hands-off ETF investment for the ages.
Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supply
Eli Lilly and Novo Nordisk are boosting supply of their weight loss drugs, while Apple Watch's heart monitoring tech was approved for use in clinical studies.
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy.
Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.
LLY February 2025 Options Begin Trading
Sigyn Therapeutics Discloses Publication of "Sigyn Therapy, an Emerging Candidate to Address Endotoxemia, Sepsis, and Drug-Resistant Viral & Bacterial Infections"
SAN DIEGO, CA - (NewMediaWire) - May 07, 2024 - Sigyn Therapeutics, Inc. (“Sigyn Therapeutics”, “Sigyn” or the “Company”) (OTCQB: “SIGY”), a development-stage medical technology company, announced today that it has published an article entitled: “Sigyn TherapyTM, an Emerging Candidate to Address Endotoxemia, Sepsis, and Drug-Resistant Viral & Bacterial Infections.” Please note that the information provided in this publication is for informational purposes only and does not constitute an offer to sell, nor is a solicitation to acquire shares of Sigyn Therapeutics.
Sigyn Therapeutics Discloses Publication of "Sigyn Therapy, an Emerging Candidate to Address Endotoxemia, Sepsis, and Drug-Resistant Viral & Bacterial Infections"
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Why Eli Lilly Stock Jumped by 4% Today
The company's payout is far from the only reason investors like the stock these days, but it certainly helps.
Why Eli Lilly Stock Jumped by 4% Today
The company's payout is far from the only reason investors like the stock these days, but it certainly helps.
Monday's session: top gainers and losers in the S&P500 index
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday.
3 Biotech Stocks to Double Your Money in the Next 24 Months
The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates.
See How Eli Lilly Ranks Among Analysts' Top Picks With Strong Buyback Activity
Lilly Declares Second-Quarter 2024 Dividend
/PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2024 of $1.30 per share on...
Investors Pile Into Amgen in Search of Next Obesity Drug Payout
Investors who may have missed out on the blistering rally in Eli Lilly & Co. and Novo Nordisk A/S are once again taking a chance with Amgen Inc.
Investors Pile Into Amgen in Search of Next Obesity Drug Payout
(Bloomberg) -- Investors who may have missed out on the blistering rally in Eli Lilly & Co. and Novo Nordisk A/S are once again taking a chance with Amgen Inc.Most Read from BloombergTruce Talks Drag as Hamas Hits Israel Crossing in Deadly AttackBuffett Praises Apple After Trimming It, Drops Paramount StakeFrance’s Macron Calls for Reset of Economic Ties With ChinaTreasury Rally Risks Running Into a $125 Billion Brick WallXi Begins Europe Tour in Paris as Macron Seeks to Reset TiesThe shares sur
2 Top Stocks That Could Make You Richer in 2024
Here are a couple of great ideas on where to invest your money today.
3 Super-Safe Dividend Stocks That Have Been Making Recurring Payments for 130+ Years
These stocks have rock-solid businesses and they have impressive track records for paying dividends.
3 Super-Safe Dividend Stocks That Have Been Making Recurring Payments for 130+ Years
These stocks have rock-solid businesses and they have impressive track records for paying dividends.
Within a few years, generative AI will be designing new drugs all on its own
It won't be long for artificial intelligence can handle drug discovery for pharmaceutical companies without human scientists.
3 No-Brainer Stocks to Buy in May
These great stocks are great picks for investors as spring winds down.
Move Over, Mounjaro. Eli Lilly Has Another Blockbuster in the Making
Eli Lilly has made inroads in the red-hot weight-loss market thanks to its diabetes blockbuster, Mounjaro.
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
Where there's a will, there's a way. And Pfizer appears to have the will to stake a claim in the massive obesity drug market.
Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?
The anti-obesity medication stock is way up, and there could be more fuel in the tank.
Why Amgen Stock Zoomed Nearly 12% Higher Today
The company delivered solid quarterly results, but its discussion of an investigational drug is what really gave its shares a pop.
Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market
Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
Noteworthy Friday Option Activity: LLY, FLR, SBUX
3 Under-The-Radar Stocks That Could Be Worth Over $1 Trillion by 2030
These under-the-radar stocks have the potential to reach a $1 trillion valuation by 2030 as they gain momentum in their respective industries.
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
The Nasdaq regained its 50-day line Friday. The other indexes hit resistance.
These S&P500 stocks are moving in today's session
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.
Gapping S&P500 stocks in Friday's session
These S&P500 stocks are gapping in today's session
What's going on in today's session: S&P500 movers
Top movers analysis one hour before the close of the markets of S&P500 on 2024-04-30: top gainers and losers in today's session.
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday.
Let's delve into the developments on the US markets in the middle of the day on Tuesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Tuesday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session.
Looking for the S&P500 stocks that are experiencing notable gaps on Tuesday? Find out which stocks are gapping up and gapping down in the S&P500 index during today's session.
Get insights into the top gainers and losers in the S&P500 index of Tuesday's pre-market session.
Top S&P500 movers in Tuesday's pre-market session